Author

Andy Blake-Haskins

Observed names: A. Blake-Haskins, A.J. Blake-Haskins

Institution: Pfizer (United States)

Observed institution: Pfizer (United States)

OpenAlex ID: A5008012629

Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.

2014 · Neil Howard Segal, Scott Joseph Antonia, et al. · Journal of Clinical Oncology · 172

A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.

2014 · Jose Lutzky, Scott Joseph Antonia, et al. · Journal of Clinical Oncology · 104

Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.

2014 · Julie R. Brahmer, Naiyer A. Rizvi, et al. · Journal of Clinical Oncology · 77

A Phase I Multi-Arm Dose-Expansion Study of the Anti-Programmed Cell Death-Ligand-1 (Pd-L1) Antibody Medi4736: Preliminary Data

2014 · N.H. Segal, O. Hamid, et al. · Annals of Oncology · 57

Clinical Activity and Safety of Medi4736, an Anti-Pd-L1 Antibody, in Patients with Head and Neck Cancer

2014 · M. Fury, S.I. Ou, et al. · Annals of Oncology · 32

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.

2022 · Thomas Powles, Se Hoon Park, et al. · Journal of Clinical Oncology · 27

Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors.

2014 · David Fairman, Rajesh Narwal, et al. · Journal of Clinical Oncology · 26

A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in subjects with advanced non–small cell lung cancer.

2014 · Mary Colleen Pinder, Naiyer A. Rizvi, et al. · Journal of Clinical Oncology · 7

203 Population pharmacokinetics of MEDI4736, a fully human antiprogrammed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors

2015 · X. Song, M. Pak, et al. · European Journal of Cancer · 6

A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Medi4736, an Anti-Programmed Cell Death-Ligand 1(Pd-L1) Antibody, in Combination with Tremelimumab in Patients with Advanced Non-Small Cell Lung Cancer (Nsclc)

2014 · S.J. Antonia, S. Goldberg, et al. · Annals of Oncology · 5

Clinical Activity and Safety of Medi4736, an Anti-Programmed Cell Death-Ligand 1 (Pd-L1) Antibody, in Patients with Non-Small Cell Lung Cancer

2014 · S. Antonia, S. Ou, et al. · Annals of Oncology · 4

Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma.

2014 · Michael S. Gordon, Jose Lutzky, et al. · Journal of Clinical Oncology · 3

Phase 1 Study Evaluating Safety and Tolerability of Medi4736, an Anti-Programmed Cell Death Ligand-1 (Pd-L1) Antibody, in Combination with Dabrafenib and Trametinib or Trametinib Alone in Patients with Unresectable or Metastatic Melanoma

2014 · M.S. Gordon, J. Lutzky, et al. · Annals of Oncology · 2

Works count: 13

Citation count: 522

H-index: 7

I10-index: 7